Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Chemoprevention Clear all

Conditions: Basal Cell Carcinomas
Interventions: Vismodegib, Placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Breast Cancer
Interventions: Tamoxifen; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 25 Years to 45 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2006
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Prevention of HIV Infection, STI Prevention
Interventions: Juntas Adelante: A Peer coaching Intervention to Promote Chemoprophylaxis for HIV Prevention among Latina Transgender Women in the Washington DC Metropolitan Area.; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pancreatic Cyst, Pancreatic Mucinous Cystic Neoplasm
Interventions: Tamoxifen 20mg; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: B-cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Interventions: lenalidomide, laboratory biomarker analysis, lymph node biopsy, bone marrow aspiration, pharmacological study, flow cytometry; Drug · Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Colon Cancer, Adenoma, Colonic Polyps
Interventions: Folic Acid; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prostate Cancer
Interventions: eflornithine, Placebo; Drug
Lead sponsor: Thomas E. Ahlering; Other
Eligibility: 35 Years to 70 Years · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: DCIS
Interventions: Anastrozole; Drug
Lead sponsor: Rita Sanghvi, Mehta; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Orange, California

Conditions: Cancer
Interventions: Genistein; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cirrhosis, Liver, Advanced Liver Fibrosis
Interventions: erlotinib hydrochloride, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Colorectal Cancer
Interventions: aspirin, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 30 Years to 74 Years
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2006
U.S. locations: 41
States / cities: Scottsdale, Arizona • San Francisco, California • Miami Beach, Florida + 37 more

Conditions: Cirrhosis, Liver
Interventions: Epigallocatechin gallate (EGCG), Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lung Cancer
Interventions: celecoxib; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 45 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Breast Neoplasms
Interventions: fenretinide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Precancerous Conditions
Interventions: Erlotinib & Celecoxib; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Non-melanomatous Skin Cancer
Interventions: acitretin, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 11
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 8 more

Conditions: Colorectal Cancer
Interventions: Curcumin C3 tablet; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Primary Sclerosing Cholangitis, Trisomy 7, Cholangiocarcinoma, Chemoprevention
Interventions: Erlotinib (Tarceva); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Neoplasm, Hereditary Nonpolyposis
Interventions: Celecoxib (SC-58635); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Raloxifene followed by combination therapy, Exemestane followed by combination therapy; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: celecoxib, placebo; Drug · Other
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 20 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2010
U.S. locations: 2
States / cities: Beltsville, Maryland • Bethesda, Maryland

Conditions: Colorectal Cancer, Familial Adenomatous Polyposis
Interventions: Celecoxib, Placebo, eflornithine, Laboratory biomarker analysis, Questionnaire administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer
Interventions: Enzalutamide; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention

Tamoxifen-MRI Study

Juntas Adelante: A Peer-Coaching Intervention to Promote Chemoprophylaxis for HIV Prevention Among Latina Transgender Women in the Washington DC Metropolitan Area.

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Chemoprevention With Folic Acid

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women

A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor

Erlotinib for Hepatocellular Carcinoma Chemoprevention

Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

EGCG for Hepatocellular Carcinoma Chemoprevention

Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation

Curcumin Biomarkers

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease

Protocol for Women at Increased Risk of Developing Breast Cancer

Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

Enzalutamide for Bladder Cancer Chemoprevention